Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.54 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.54 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.54 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.54 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.54 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4F8 | P98187 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30728871 | 1.00 | ACHE (0.55) | ACHECYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL15906120 | 0.87 | ACHE (0.52) | ACHECYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL4925801 | 0.86 | CYP1A1 (0.69) | ACHECYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL14003485 | 0.86 | MAPT (0.49) | CYP3A4ALDH1A1SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL277912 | 0.84 | ACHE (0.57) | ACHECYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL18087597 | 0.84 | SMARCA2 (0.46) | ACHECYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL18087562 | 0.84 | MAOB (0.53) | ACHEHDAC4HDAC2HDAC8MAOB | |
| SCHEMBL18087565 | 0.84 | LMNA (0.58) | ACHECYP3A4HDAC4HDAC2HDAC8 | |
| SCHEMBL30112655 | 0.83 | CYP3A4 (0.69) | ACHECYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL1673262 | 0.82 | PTGDR2 (0.58) | ACHECYP3A4MAOBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066072-B1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIV KANSAS (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIVERSITY OF KANSAS (US) | 2016-09-22 | — | — | US | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015070238-A2 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| WO-2011041593-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010096650-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | ACHE 4641/4885CYP1A1 4388/4885CYP1A2 4367/4885 |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | ACHE 4046/4885CYP1A1 205/4885CYP1A2 525/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | ACHE 4861/4885CYP1A1 3699/4885CYP1A2 3257/4885 |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | ACHE 4813/4885CYP1A1 84/4885CYP1A2 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.